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bstract
Strong epidemiologic evidence suggests an association between Alzheimer disease (AD) and type 2 diabetes. To determine if amyloid beta
A) and hyperphosphorylated tau occurs in type 2 diabetes, pancreas tissues from 21 autopsy cases (10 type 2 diabetes and 11 controls) were
nalyzed. APP and tau mRNAs were identified in human pancreas and in cultured insulinoma beta cells (INS-1) by RT-PCR. Prominent APP
nd tau bands were detected by Western blotting in pancreatic extracts. Aggregated A, hyperphosphorylated tau, ubiquitin, apolipoprotein
, apolipoprotein(a), IB1/JIP-1 and JNK1 were detected in Langerhans islets in type 2 diabetic patients. A was co-localized with amylin
n islet amyloid deposits. In situ beta sheet formation of islet amyloid deposits was shown by infrared microspectroscopy (SIRMS). LPS
ncreased APP in non-neuronal cells as well. We conclude that A deposits and hyperphosphorylated tau are also associated with type 2
iabetes, highlighting common pathogenetic features in neurodegenerative disorders, including AD and type 2 diabetes and suggesting that
 deposits and hyperphosphorylated tau may also occur in other organs than the brain.
2008 Elsevier Inc. All rights reserved.
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. Introduction
Strong epidemiologic evidence supports an association
etween Alzheimer’s disease (AD) and type 2 diabetes
Janson et al., 2004; Ott et al., 1999; Ristow, 2004; Voisin
t al., 2003). AD is a neurodegenerative disorder character-
zed by a slowly progressive dementia and brain atrophy.
he degenerative process affects primarily the neocortical
∗ Corresponding author. Tel.: +1 41 79 207 4442.
E-mail address: judithmiklossy@bluewin.ch (J. Miklossy).
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nd limbic cortices, where there is an accumulation of senile
laques mainly consisting of beta amyloid protein (A)
eposits and neurofibrillary tangles (NFTs), mainly consist-
ng of hyperphosphorylated tau.
Type 2 diabetes formerly termed noninsulin-dependent
iabetes mellitus (NIDDM), or adult-onset diabetes, is char-
cterized by a slowly progressive degeneration of islet
-cells, resulting in a fall of insulin secretion and decreased
nsulin action on peripheral tissues. Type 2 is the most com-
on form of diabetes, comprising 90–95% of all diabetic
ases (O’Brien et al., 2003). Its etiology is multifactorial and
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ts pathogenesis has been not completely resolved. The extent
f amyloid deposition is associated with the severity of beta
ell loss and the impairment in insulin secretion and glucose
etabolism, suggesting a causative role for islet amyloid in
he degenerative process in type 2 diabetes (Hull et al., 2004).
Deposition of amyloid material is a major pathological
eature of both AD and type 2 diabetes. In AD, the amyloid
eposits consist mainly of aggregates of beta amyloid pro-
ein (A). A includes peptides of 40 and 42–43 amino acid
ength which accumulate following proteolytic cleavage of
myloid beta precursor protein (APP). The exact physiolog-
cal function of A is not known.
Islet amyloid deposits are present in more than 95% of
ype 2 diabetic patients (Lopes et al., 2004). The extent of
slet amyloid deposits correlates with the clinical severity of
he disease (Cooper et al., 1987a,b). The deposits are mainly
omprised of amylin, also known as islet amyloid polypeptide
IAPP) (Cooper et al., 1987a,b; Westermark et al., 1987). This
7 amino acid peptide is derived by proteolytic cleavage of the
9-amino acid islet amyloid precursor protein (Cooper et al.,
987a,b; Sanke et al., 1988). It has been suggested that amylin
s a hormone, related to the calcitonin/calcitonin gene-related
eptide family, and is involved in homeostatic maintenance
Cooper et al., 1988). Along with insulin, amylin is produced
y -cells in the Langerhans islets of the pancreas. Because
f the accumulating evidence that a link exists between AD
nd type 2 diabetes, we investigated whether A deposits
nd phosphorylated tau aggregates may also develop in the
ancreas in type 2 diabetes. Analysis of the in situ infrared
o
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ntibodies utilized in the current study.
ntigen Antibody (ref.) Source
F/3D, M0872 A 8–17 DakoCytomatio
G8 A 17–24 Sigma–Aldrich
F9AF A 17–28
 1–40 C terminus KHB3481 QCB, Hopkinto
 1–42 C terminus 88–344 QCB, Hopkinto
1F12 A 1–42 Johnson-Wood e
 A 1–40 Dr. H. Mori
 A 1–42 Dr. H. Mori
PP, 22C11 MAB348 Chemicon, Tem
mylin(1) IAPP 1–37 Gift of Dr. A. C
mylin(2) IAPP 1–37 Gift of Dr. A. C
mylin a.a. 29–37 GTX 74673 GeneTex, Inc.
au A0024 DakoCytomatio
au T-6402 Sigma
au T-5530 Sigma–Aldrich
au, clone tau 2 MAB375 Chemicon
nti-phospho-tau pSer409 Sigma–Aldrich
T-8 BR-03 Endotellin
au C3 L. I. Binder (No
biquitin Z 0458 DakoCytomatio
po-E 0650-1904 Biogenesis
po-E 1062 Chemicon
polipoprotein-a Marcovina et al. (1995)
B-1 Pellet et al. (2000)
NK-1 56GB Cell signaling
rb-2 G16720-050 BD Transd. Labging 31 (2010) 1503–1515
icrospectra of islet amyloid deposits was also performed
o detect the typical secondary protein structure using syn-
hrotron infrared microspectroscopy (SIMRS).
The bacterial lipopolysaccharide (LPS), a powerful
nflammatory stimulator, induces increased APP levels and
ncreased A 1–42 in vitro in neuronal cell cultures and in
ivo in the central nervous system. Insulin decreases APP in
eurons and therefore has a protective effect. Whether LPS
nd insulin may also influence APP levels in non-neuronal
ells is not known. We used Western blot analysis to test
hether LPS and recombinant human insulin may also influ-
nce APP levels in non-neuronal TE671 and U87MG cells
ompared to PC12 cells.
. Methods
.1. Autopsy cases
Pancreas tissue of 21 autopsy cases was analyzed
Table 2). Ten of the 21 cases had clinically and patholog-
cally confirmed type 2 diabetes (average age: 75.69; range
3–98) with one having a concurrent pancreatic cancer. All
iabetic patients had long standing noninsulin-dependent dia-
etes (NIDDM) except one (case 13 of Table 2). This 78 year
ld patient with two decades history of severe type 2 diabetes
as had become insulin-dependent several years before death
case 13, Table 2). The other eleven patients with no clinical
r pathological record of type 2 diabetes were used as controls
Type Dilution
n Mouse IgG 1:1000
Mouse IgG 1:100
Mouse IgG 1:400
n, MA Rabbit IgG 1:500
n, MA Rabbit IgG 1:500
t al. (1997) Mouse IgG 1:500
Rabbit IgG 1:200
Rabbit IgG 1:200
ecula, CA Mouse IgG 1:500
lark Rabbit IgG 1:400
lark Rabbit IgG 1:100
Mouse IgG 1: 200
n Rabbit IgG 1:200
Rabbit IgG 1:1000
Mouse IgG 1:200
Mouse IgG 1:500
Mouse IgG 1:100
Mouse IgG 1:100
rthwestern University, Chicago) Mouse IgG 1:5000
n Rabbit IgG 1:200
Goat IgG 1:100
Mouse IgG 1:100
Mouse IgG 1:100
Rabbit IgG 1:100
Rabbit IgG 1:100
Mouse IgG 1:1000
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Table 2
Illustration of the results of the immunohistochemical analysis.
Case Dg Age Sex A A (p)Tau Ubi Apo-E Apo(a) IB1 JNK-1
1 T2D 76 M + + + + + + + +
2 T2D 70 M + + + + + + + +
3 T2D 98 F + + + + + + − −
4 T2D 69 F + + + + + + + +
5 T2D 79 M + + + + + + + +
6 T2D 77 M + + + + + + + +
7 T2D 77 F + + + + + + + +
8 T2D 73 M + + + + + + + +
9 T2D 73 F + + + + + + + +
10 T2D 66 F + + + + + + + +
11 T2D 75 M + + + + + + + +
12 T2D 73 F + + + + + + + +
13 T2D 78 M + + + + − − − −
14 CTR 78 F 0 0 0 0 − − − −
15 CTR 76 F 0 0 0 0 0 0 0 0
16 CTR 69 F 0 0 0 0 0 0 0 0
17 CTR 60 M 0 0 0 0 0 0 − −
18 CTR 70 M 0 0 0 0 0 0 0 0
19 CTR 75 F 0 0 0 0 0 0 0 0
20 CTR 73 M + + + + + + + +
21 CTR 76 F + + + + + + + +
22 CTR 56 M 0 0 0 0 0 0 0 0
23 CTR 54 F 0 0 0 0 0 0 0 0
24 CTR 67 M 0 0 0 0 0 0 0 0
Abbreviations: Dg: diagnosis; A: islet amyloid polypeptide as verified by thioflavin S and anti-amylin immunostaining; A: beta amyloid; (p)Tau: hyper-
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phosphorylated tau; Ubi: ubiquitin; Apo-E: apolipoprotein-E; Apo(a): apol
IB1/JIP-1); JNK-1: c-Jun NH2-terminal kinase-1; T2D: type 2 diabetes; C
as not performed.
average age: 68.54; range 54–78). In these cases with normal
ugar level, specific tests for diabetes were not performed and
othing in favor of diabetes was clinically recorded. The time
apse between death and autopsy varied between 6 and 24 h
n type 2 diabetic cases and between 8 and 30 h in control
utopsy cases. The use of post mortem delays between 6 and
0 h has guaranteed a consistent and comparable quality of
he material used for the histological and molecular analyses,
ncluding the mRNA analysis (Yasojima et al., 2001).
In each case, a sample of about 2 cm × 1 cm × 0.5 cm was
issected from the pancreas and frozen in liquid N2 or at
80 ◦C until processing. These samples were used for molec-
lar biological and immunohistochemical analyses. A further
ample was taken for embedding in paraffin and was used for
istochemical and immunohistochemical investigations.
.2. Cell lines
Rat insulinoma INS-1 cell line (Asfari et al., 1992) was
ultured in RPMI 1640 medium containing 11.1 mmol/l
lucose and supplemented with 10% fetal calf serum,
mmol/l l-glutamine, 1 mmol/l sodium pyruvate, 50mol/l
-mercaptoethanol, penicillin (50 U/ml), and streptomycin
50 U/ml) (Martin et al., 2003).
Cells of the human neuroblastoma SH-SY5Y cell line
ATCC CRL-2266; a gift from Dr. R. Ross, Fordham
niversity, NY) were grown in Dulbecco modified Eagle
edium-nutrient mixture F12 Ham (DMEM-F12) supple-
t
L
p
sein(a); IB1: Islet-brain-1 or C-Jun N-terminal kinase interacting protein-1
ntrol; +: positive immunoreaction; 0: no immunoreaction; −: the analysis
ented with 10% fetal bovine serum (FBS; GIBCO BRL,
ife Technologies, Burlington, ON, Canada) containing
0g/ml gentamicin (Miklossy et al., 2006). RNA and pro-
ein extracts of these cells, which are known to contain APP
nd tau, were used as positive controls for the detection of
PP and tau in pancreas tissues and in INS-1 beta cells.
N2a neuroblastoma cells were obtained from the Amer-
can Type Culture Collection (ATCC) and cultured in the
ame medium as SH-SY5Y cells. N2a cells contain APP and
au and were used as an additional positive control for the
etection of APP and tau in pancreas tissues and in INS-1
eta cells. N2a cells over-expressing APP were also used as
ositive control for Western blot analysis of APP. Transient
ransfection was carried out using the APP695swe plasmid
kindly provide by Dr. Weihong Song, Brain Research Center,
niversity of British Columbia, Canada) using Lipofec-
AMINE2000 (Invitrogen) according to the manufacturer’s
nstructions. For transient transfection, cells were grown to
bout 90% confluence and transfected with the plasmids.
ells were harvested 48 h following transfection.
Rat pheochromocytoma PC12 cells (ATTC, CRL-1721)
howing neuronal characteristics by expressing cate-
holamines, dopamine and norepinephrine (0.3 × 106), were
lated into collagen coated Petri dishes (100 mm) and cul-
ured in 10 ml of F12 Nutrient Mixture (HAM, 11765-054,
ife Technologies, Gibco/BRL, Frederick, Maryland) sup-
lemented with 10% horse serum, 5% FBS, 1% penicillin/
treptomycin and 870 mg NaHCO3 per 500 ml medium.
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Human TE 671 cells (subline No. 2; ATCC, HTB-139)
howing characteristics of striated muscle expressing myo-
lobin and desmin (0.3 × 106) and human U87MG cells
howing characteristics of glial cells were plated in 100 mm
etri dishes and were cultured in DMEM containing 10%
etal bovine serum (FBS) and 1% penicillin/streptomycin in
humidified, 6% CO2 incubator at 37 ◦C.
.3. RNA isolation and cDNA synthesis by reverse
ranscription
RNA was extracted from 100 mg fresh pancreas tissue
amples of 9 patients (6 with type 2 diabetes and 3 con-
rols) and from harvested INS-1 islet beta cells and SH-SY5Y
ells using TRI-Reagent (Invitrogen, Life Technologies,
urlington, ON, Canada) following the instructions of the
anufacturer. Samples (100 mg) of the frontal cortex in four
atients (3 with type 2 diabetes and 1 control) were also
nalyzed and were used as positive controls. Two g of
NA extract was treated with 10 U of DNase I (Invitrogen
ife Technologies, Burlington, ON, Canada) for 60 min at
7 ◦C in 25l of 1× reverse transcription buffer (50 mM
ris–HCl, 75 mM KCl, 3 mM MgCl2) containing 40 U of
Nase inhibitor (Amersham Biosciences, Baie d’Urfé, PQ,
anada) and 1 mM dithiothreitol (DTT). This was followed
y incubation at 85 ◦C for 5 min to inactivate the enzyme.
everse transcription was performed at 42 ◦C for 90 min
n 50l of the following mixture: 1× reverse transcription
uffer containing 2g of RNA, 5 mM DTT, 0.2g random
examer primers (Amersham Biosciences), 1 mM deoxynu-
leotides (Invitrogen Life Technologies), 40 U of RNase
nhibitor, and 400 U of SuperScript II reverse transcriptase
Invitrogen Life Technologies). At the end of the incubation
eriod, the enzyme was inactivated by heating at 65 ◦C for
0 min.
One microliter of the transcription reaction solution was
mplified by polymerase chain reaction (PCR) for APP and
au. The PCR reaction was carried out in a 25l mixture con-
aining 1× GeneAmp PCR buffer II (Applied Biosystems,
treetsville, ON, Canada), 1.25 U of AmpliTaq Gold DNA
olymerase (Applied Biosystems), 2 mM MgCl2 (Applied
iosystems), 200M dNTPs (Invitrogen Life Technologies,
urlington, ON, Canada), and 0.5M of each primer. The
mplification program consisted of an initial denaturation
tep at 94 ◦C, which was extended to 9 min in order to activate
mpliTaq Gold enzyme. This was followed by an annealing
tep at 55 ◦C for 1 min and an initial synthesis step at 72 ◦C
or 3 min. The remaining cycles were 1 min at 94 ◦C, 1 min
t 55 ◦C and 1 min at 72 ◦C. The number of cycles performed
as 25–30.
The following primers were used for the amplification of
PP and tau. APP gene-specific forward 5′-CGGAATTCC-
TTGGTGTTCTTTGCAGAAG-3′ and reverse 5′-CGGA-
TTCCGTTCTGCATCTGCTCAAAG-3′ primers were
sed to amplify a 248 bp fragment of the APP coding region.
he TAU gene-specific forward primer 5′-GCCAACGCCA-
t
s
pging 31 (2010) 1503–1515
CAGGATTC-3′ and reverse primer 5′-AGTAGCC-
TCTTCCGCC-3′ were used to amplify a 221 bp fragment
f the tau coding region. Glyceraldehyde 3-phosphate dehy-
rogenase (GAPDH), a key enzyme involved in glycolysis,
hich is constitutively expressed at high levels in almost all
issues was amplified in the same conditions and was used
s a loading control. GAPDH gene-specific forward primer
′
-CATGCCGCCTGGAGAACCTGCCA-3′ and reverse
rimer 5′-TGGGCTGGGTGGTCCAGGGGTTTC-3′ were
sed to amplify a 251 bp fragment of GAPDH. After amplifi-
ation, PCR products were separated on 2% agarose gel and
isualized by incubation for 10 min in a solution containing
0 ng/ml of ethidium bromide. Polaroid photographs of the
els were taken by Kodak Image Station 1000 software
PerkinElmer, Norwalk, CT, USA).
.4. Immunoblotting
Frozen pancreas tissue samples of six patients (4 patients
ith type 2 diabetes and two controls) and harvested N2a cells
ere homogenized in 5 volumes of RIPA-Doc lysis buffer
ontaining 50 mM Tris–HCl (pH 7.5), 150 mM NaCl, 1%
odium deoxycholate, 1% Triton X-100, 0.1% sodium dode-
yl sulfate (SDS), and protease inhibitor cocktail (Complete,
697 498, Roche Molecular Biochemicals, Indianapolis, IN).
he homogenates were centrifuged at 100,000 × g for 1 h at
◦C. The supernatant was taken and the protein concentra-
ion was determined using DCTM Protein Assay (Bio-Rad
aboratories Inc., CA). Samples containing 100g protein
ere separated by 7.5% SDS-PAGE under reducing condi-
ions and the proteins in the gel were electrotransferred onto
polyvinylidene fluoride (PVDF) membrane (Millipore Co.,
edford, MA). After blocking with 5% (w/v) skim milk in
BS containing 0.1% Tween 20, the membranes were incu-
ated with the primary antibodies overnight at 4 ◦C. To detect
PP a monoclonal anti-APP antibody, clone 22C11 was used
MAB348, Chemicon, Temecula, CA) which recognizes an
terminal common epitope (a.a. 66–81) in the three major
soforms of APP. For the detection of tau, a monoclonal anti-
ody clone tau 2 (MAB375, Chemicon) was used which
ecognizes both non-phosphorylated and phosphorylated tau.
ollowing incubation of the membranes with the appropriate
orseradish peroxidase (HRP)-conjugated anti-mouse (Cell
ignaling Technology, Danvers, MA, USA, dilution 1:1000)
r anti-rabbit antibody (Cell Signaling Technology, Danvers,
A, USA, dilution 1:1000) for 1 h at room temperature,
mmunoreactivity was visualized by chemiluminescence
sing ECL Western blotting system (Amersham Pharmacia
iotech, Uppsala, Sweden) and recorded on Hyperfilm ECL.
.5. Histochemical and immunohistochemical analysisFrozen (10m) and paraffin embedded (5m) serial sec-
ions were subsequently cut and mounted directly on glass
lides. The frozen sections were post fixed overnight with 4%
araformaldehyde prior to immunohistochemical analysis.
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Paraffin and 4% paraformaldehyde fixed sections
mounted or floating) of pancreas were stained with hema-
oxylin and eosin (H&E) and with Thioflavin S and congo Red
o detect amyloid deposits. For immunohistochemical analy-
is, antibody type, specificity and source are given in Table 1.
o detect islet amylin deposits, two rabbit polyclonal antibod-
es and one monoclonal antibody (clone R10/11, GeneTex,
nc.) to human amylin were used. To detect A, paraffin sec-
ions and frozen sections post fixed in 4% paraformaldehyde
ere immunostained with 8 different anti-A antibodies.
hese recognized several epitopes of the peptide, including
 8-17 (6F/3D), A17-24 (4G8), A17-28 (2F9AF), A40
QCB1-40) and A42 (QCB1-42, 21F12). Two polyclonal
ntibodies, A40 and A42, which recognize the C-terminus
f A40 and A42 respectively, were also utilized (generous
ifts of Dr. H. Mori). For detection of A, the sections were
re-treated with 80% formic acid for 20 min before immuno-
taining. To detect tau, the sections were immunostained
ith three monoclonal antibodies (Sigma T-5530, Chemicon
au-2, and AT8 Innogenetics) and two polyclonal anti-
odies (T-6402, Sigma and A0024, DakoCytomation). The
onoclonal tau-2 antibody and the two anti-tau polyclonal
ntibodies bind both, phosphorylated or non-phosphorylated
orms of tau. These antibodies do not show cross-reactivity
ith other microtubule associated proteins. The antibody AT-
recognizes tau phosphorylated at residues Ser-202/Thr-205.
he anti-phospho-tau Ser409 (Sigma–Aldrich) antibody rec-
gnizes tau at phosphorylated Ser 409. These antibodies do
ot cross-react with non-phosphorylated tau.
Pancreas sections were also immunostained with a
olyclonal anti-ubiquitin antibody (DAKO, Z 0458) and
monoclonal anti-apolipoprotein-E antibody (MAB1062,
hemicon). Not only the apoE epsilon 4 allele, but
ipoprotein-a (apo(a) is also a risk factor for late onset AD
Mooser et al., 2000). In order to analyze whether apo(a)
ay be present in association with islet amyloid deposits in
ype 2 diabetes, immunostaining with a mouse monoclonal
nti-apo(a) antibody (Marcovina et al., 1995) was performed.
Islet-brain-1 or C-Jun N-terminal kinase interacting
rotein-1 (IB1/JIP-1) and c-Jun NH2-terminal kinase (JNK),
ere both found to be co-localized with phosphorylated tau
n neurofibrillary tangles in AD (Helbecque et al., 2003). In
rder to analyze whether they may also be associated with
egenerating lesions of the pancreas in type 2 diabetes, a rab-
it affinity purified anti-IB1/JIP1 polyclonal antibody (Pellet
t al., 2000) and a rabbit monoclonal anti-JNK-1 antibody
Cell signaling, 56G8) were employed.
For antibody detection, the avidin–biotin–peroxidase
echnique was utilized as previously described in detail
Miklossy et al., 2006). Control sections, in which the pri-
ary antibody was replaced by normal serum, were always
mmunostained in parallel.
A double immunofluorescence technique to detect over-
apping co-expression of A and amylin was also carried out
n pancreas sections of patients with type 2 diabetes. The
ections were incubated with a mixture of rabbit anti-human
2
eging 31 (2010) 1503–1515 1507
 (A-40 or A-42, dilution 1:100, kind gift of Dr. Mori)
nd a mouse monoclonal antibody to amylin (GTX74673,
eneTex, Inc., dilution 1:100) overnight at room temper-
ture. The sections were next incubated for 1 h at room
emperature with FITC-conjugated swine anti-rabbit anti-
ody (DAKO; F0205, 1:30) to detect the green fluorescence
f A. After washing 3× 5 min with PBS, the sections were
ncubated with a TRITC-tagged rabbit anti-mouse antibody
1:100, DAKO, R0270, 1:30) to yield a red fluorescence for
mylin. The sections were then mounted with Fluoromount-
(Southern Biotechnology Associates Inc., Birmingham,
L) and examined with a Carl Zeiss Axi-overt-200 flu-
rescence microscope. The capture of the green amylin
uorescence, and the red fluorescence of A as well as the
erged images were performed using the Northern Elite pro-
ram. Control sections with the omission of the primary
ntibodies were also prepared for the double immunofluo-
escence analyses.
A combination of immunostaining with antibodies to the
arious pathological proteins with Thioflavin S staining was
lso used to analyze their localization related to islet amyloid
eposits. These doubly stained sections were analyzed with
he same Carl Zeiss Axi-overt-200 fluorescence microscope,
ith and without fluorescent filters, enabling us to observe
he localization of pathological proteins in bright field and
reas of islet amyloid deposits by their green fluorescence.
.6. Synchrotron infrared microspectroscopy (SIRMS)
The in situ infrared microspectroscopic analysis of
slet amyloid deposits was performed using a Spectra
ech Continum infrared microscope coupled to a Nico-
et Magna 860 FTIR where the conventional infrared
ource was replaced by a synchrotron light from Beam-
ine U10B (National Synchrotron Light Source, Brookhaven
ational Laboratory) equipped with a fluorescence micro-
cope. Unfixed 8m thick frozen sections of the pancreas
rom three patients with type 2 diabetes were placed on
nfrared-transparent BaF2 slides and stained with Thioflavin
. The in situ infrared microspectra of Thioflavin S positive
slet amyloid deposits showing green fluorescence was com-
ared with that obtained by analyzing unaffected areas of
he pancreas without amyloid deposits. Infrared microspec-
ra were collected in transmission mode, 128 scans per
oint, 4 cm−1 resolution using Atls software (Thermo Elec-
ron). The final data format was absorbance, where the
ackground was collected open beam. Protein secondary
tructure was determined by Amide I infrared absorption
and (1600–1700 cm−1) analysis. The frequency of Amide
band is sensitive to protein secondary structure, where -
heet conformation absorbs near 1630 cm−1..7. Exposure of cells to LPS and insulin
TE671, U87MG or PC12 cells at 70% confluence were
xposed to 500 ng/ml LPS or to 100 ng/ml human recombi-
1 ogy of Aging 31 (2010) 1503–1515
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Fig. 2. Detection of APP and tau in human pancreas tissue by Western
blot. Immunoblotting using a monoclonal anti-APP antibody (clone C2212)
which recognizes a common N terminal epitope of the three major APP iso-
forms detects immunoreactive APP bands around 120 kDa in three pancreas
samples (lanes 1–2 correspond to controls and lane 3 to type 2 diabetes)
when compared to N2a human neuroblastoma cells which are known to
c
T
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ant insulin (Roche, 1 376 497). For immunoblotting whole
ell extracts were prepared following 0 h, 30 min, 6, 24 and
8 h of LPS and insulin exposures. For insulin exposure an
dditional extract at 3 h exposure was also analyzed. Follow-
ng these various exposure times the cells were harvested by
entrifugation and the Western blot detection of APP and tau
as performed as described above.
. Results
.1. RNA isolation and cDNA synthesis by reverse
ranscriptionFig. 1 shows the expression of APP and tau mRNAs by
T-PCR in human pancreas tissues of five patients (Fig. 1A).
n the four additional cases where fresh brain tissue was
lso available for analysis the APP and tau mRNAs bands
ig. 1. Expression of APP and tau. mRNAs in human pancreas tissue, SH-
Y5Y and beta cell lines. (A) Ethidium bromide-stained agarose gel of
T-PCR products from human pancreas of 5 individuals, 3 with type 2 dia-
etes (lanes 1–3) and 2 controls (lanes 4 and 5). Molecular weight markers
re shown on the right and left side. (B) Expression of APP and tau mRNAs
n pancreas tissue of three additional diabetic (lanes 1, 3, 5) and one control
lane 7) patients compared to the frontal cortex of the same patients (lanes
, 4, 6, 8, respectively). (C) The expression of APP and tau mRNAs in cul-
ured INS-1 beta cells was compared to those of neuroblastoma SH-SY5Y
ells. Ethidium bromide-stained agarose gel of RT-PCR products from beta
ells (lane 1) compared to SH-SY5Y cells (lane 2). Molecular weight mark-
rs are shown on the left side. Glyceraldehyde 3-phosphate dehydrogenase
GAPDH) was used to verify loading conditions.
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wo tau reactive bands of ca. 64 and 69 kDa were detected with anti-tau,
lone tau 2 antibody in the same pancreas samples similar to those of N2a
euroblastoma cells.
n the pancreas and frontal cortex were identical (Fig. 1B).
he bands were also similar to those observed in INS-1 beta
ells and SH-SY5Y cells (Fig. 1B). The GAPDH mRNA was
sed to verify loading conditions.
.2. Immunoblotting
Fig. 2 illustrates immunoreactive bands of APP around
20 kDa (lanes 1–3) in pancreatic extracts identical to those
n the N2a cell line transiently transfected with APP and
herefore over-expressing APP. A tau reactive doublet was
lso detected in the pancreas of the same patients (panel tau,
anes 1–3) similar to that of the N2a cell line which is known
o express tau protein.
.3. Histochemistry and immunohistochemistry
In the pancreas of patients with type 2 diabetes, on H&E
tained sections the presence of amyloid deposits in Langer-
ans islets were often difficult to recognize (Fig. 3A outlined
ith arrows). However, in more affected areas of the pancre-
tic islets at higher magnification, the cytoplasm of some cells
howed a homogenous eosinophilic appearance, sometimes
ith fine fibrillary changes occasionally in triangular shaped
ells (Fig. 3B). Atherosclerotic changes of small and medium
ized arteries of the pancreas were frequently observed. In a
ew cases, rare discrete lymphocytic infiltrates could be seen,
articularly around the more affected areas of the pancreas,
ut in the majority of cases lymphocytic infiltrates were not
isible on H&E stained sections. Thioflavin S (Fig. 3C) and
mylin immunoreactive (Fig. 3D) islet amyloid deposits were
ound in the pancreas in the 10 clinically and pathologically
onfirmed type 2 diabetic cases. Thioflavin S and congo Red
ositive and amylin immunoreactive islet amyloid deposits
ere not observed in the pancreas of the control cases with-
ut a clinical record of type 2 diabetes, except for two cases.
hese cases may represent a preclinical stage of the disease
ince in the clinically confirmed diabetic patients the islet
myloid deposits were more extensive and occupied larger
reas of the islets.
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Fig. 3. Islet amyloid deposit in type 2 diabetes. (A) Section of the pancreas from a patient with type 2 diabetes stained with H&E. Arrows point to a Langerhans
islet, the site of amyloid deposition in type 2 diabetes, which is surrounded by acinar cells. At high magnification (B) a cell with “flame”-like triangular
shape (arrow) and homogeneous eosinophilic cytoplasm is visible. (C) Islet amyloid deposits exhibiting positive fluorescence, localized in Langerhans islets
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nti-IAPP 1–37) was used for immunostaining. Bar: (A) 150m; (B) 7m
When pancreas sections were immunostained with the
ight different anti-A antibodies, an almost identical
mmunoreaction was observed. The best results for A
mmunostaining were obtained on paraformadehyde fixed
rozen sections. Immunostaining floating sections has given
etter results compared to sections mounted on slides. In
ll diabetic patients, islet amyloid deposits showed posi-
ive A immunostaining. This positive A immunoreactivity
s illustrated for the A-42, A-40 and 4G8 antibodies in
ig. 4A–C, respectively. A positive A immunoreaction was
lso observed in the pancreas of the two clinically silent
ases with less severe islet amyloid deposits where type 2
iabetes was not clinically confirmed. Similarly to amylin,
 immunoreactivity was also observed in larger, homo-
eneous extracellular islet amyloid deposits, particularly in
ore severely affected areas, but A was also present intra-
ellularly in a subset of cells of the Langerhans islets (Fig. 4D
nd E). In some cases, scattered foci of A deposits were
bserved in pancreatic acinar cells and in the walls of pan-
reatic blood vessels showing Thioflavin S positive amyloid
eposits. When serial sections of pancreas from diabetic
atients were immunostained for A and amylin, A and
mylin were co-localized in islet amyloid deposits. Similar
esults were obtained when the same pancreas sections were
w
t
o
ndetects amyloid. (D) Amylin immunoreactive amyloid deposits localized
. Rabbit anti-amylin antibody raised against islet amyloid peptide (rabbit
0m; (D) 200m.
ouble-stained using immunofluorescent secondary antibod-
es to A and amylin (Fig. 4G–I).
With five different anti-tau-antibodies, including the
wo antibodies which recognize only phosphorylated tau,
positive immunoreaction in the degenerating pancreatic
slets was present in all pancreases of patients with type
diabetes. This is illustrated for the phosphorylation-
ndependent antibody A0024 (Fig. 5A and B) and for the
hosphorylation-dependent antibody AT8 (Fig. 5C). Positive
biquitin (Fig. 5D), Apo-E (Fig. 5E) and apo(a) (Fig. 5F)
mmunoreactions were also observed in association with islet
myloid deposits. IB1/JIP1 (Fig. 5G) and JNK-1 (Fig. 5H)
ositive immunoreactions in the cytoplasm of a subset of cells
n the Langerhans islet, similar to that of phosphorylated tau,
ere also observed in all cases with type 2 diabetes.
On immunostained sections doubly stained with Thio-
avin S the immunoreaction to A, (p)tau, ubiquitin, Apo-E,
po-a, IB1 and JNK-1 were localized in the affected Langer-
ans islets in areas with islet amyloid deposits (not shown).
Control sections where the primary antibody was replaced
ith normal serum (Fig. 5I) were always negative. Except the
wo control cases where some islet amyloid deposits were
bserved, pancreas sections of the control cases were all
egative (not shown).
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Fig. 4. A in islet amyloid deposits in type 2 diabetes. (A) Islet amyloid deposits showing positive A immunoreaction with anti-A antibodies 21F12
(A), 2F9AF (B) and 4G8 (C) which recognize different epitopes of the molecule (see Table 1). (D and E) Sections of the pancreas from a diabetic patient
immunostained with rabbit anti-amylin antibody (D, IAPP 1-37, Dr. A. Clark) and with the 4G8 monoclonal anti-A antibody (E) showing their intra-
cellular localization (arrows). (F) Small group of affected acinar cells showing A immunoreaction demonstrated with the anti-A monoclonal antibody
21F12. (G–I) Pancreas section of a patient with type 2 diabetes doubly immunostained with an anti-amylin monoclonal antibody (GTX 74673, GeneTex,
Inc.) labeled with TRITC-tagged secondary anti-mouse antibody (which gives a red fluorescence for amylin) (G) and with a polyclonal antibody to the C
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G–I) 120m.
.4. Synchrotron infrared microspectroscopy
Fig. 6 shows the in situ infrared absorption microspec-
ra of islet amyloid deposits in type 2 diabetes, as analyzed
y SIRMS which showed a protein (Amide I) absorbance
aximum near 1630 cm−1 representative of -sheet protein
tructure. In areas of the pancreas without amyloid deposits,
he absorbance maximum was near 1655 cm−1 which cor-
esponds to -helical protein structure typical of healthy
issue.
.5. Effect of LPS and insulin on APP
Increased APP levels were detected in U87MG and
E671 cells, comparable to those in PC12 cells following
xposure to 500 ng/ml of LPS. Human recombinant insulin
100 ng/ml) decreased APP levels in PC12, U87MG and
E671 cells following 6–48 h of exposure. The influence of
PS and insulin on PC12 and TE671 cells is illustrated in
igs. 7 and 8.
l
o
a
hit secondary antibody shows a green fluorescence. The orange color of the
sits. Bars: (A and C) 250m, (B) 70m, (D and E) 50m, (F) 200m,
. Discussion
Type 2 diabetes accounts for 90–95% of all diabetic cases
nd has become a major health concern (Biessels et al., 2006).
he percentage of type 2 diabetes among AD patients is sig-
ificantly higher than among age-matched non-AD controls
Kuusisto et al., 1997; Ott et al., 1999). Conversely, patients
ith type 2 diabetes have twice the risk of controls to develop
D (Arvanitakis et al., 2004; Grodstein et al., 2001; Leibson
t al., 1997; Ott et al., 1999; Peila et al., 2002; Xu et al., 2004).
Dysregulation of APP metabolism results in fibrillary A
eposits in AD brain and dysregulation of tau metabolism
esults in fibrillary hyperphosphorylated tau deposits in neu-
ons. The presence of APP and tau which have general
egulatory functions in various cells of other organs than
rain would suggest that increased APP and hyperphosphory-
ation of tau might be expected to be associated with various
ther pathological conditions as well. Indeed, A deposition
nd pathological fibrillary lesions showing similar immuno-
istochemical and ultrastructural properties to tangles and
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Fig. 5. Hyperphosphorylated tau in the pancreas in type 2 diabetes. (A–C) Pancreas sections of patient with type 2 diabetes showing a positive immunoreaction
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NK1 (H). (I) Control section where the primary antibody was replaced by
europil threads have been reported in several other organs
nd tissues than the brain (Joachim et al., 1989; Askanas
t al., 1994; Miklossy et al., 1998; Miklossy et al., 1999;
skanas and Engel, 2002; Dentchev et al., 2003; Goldstein
t al., 2003). We suspected this might be the case for the pan-
reas in type 2 diabetes and found evidence supporting this
ypothesis.
The expression of APP and tau mRNAs by RT-PCR in
uman pancreas (both in type 2 diabetes and controls) and
n INS-1 beta cells, as well as the detection of APP and tau
mmunoreactive bands by Western blot indicates that simi-
arly to the brain APP and tau are present in the pancreas
issue and in beta cells. A detailed immunohistochemical
nvestigation to detect aggregated A in pancreas tissue in
ype 2 diabetes, using a panel of anti-A antibodies recog-
izing different epitopes of A, showed that islet amyloid
eposits are also immunoreactive to A. On serial sections
r on sections doubly immunostained for A and amylin, they
ere co-localized in these deposits. Antibodies to hyperphos-
horylated tau also labeled a subset of cells in the affected
angerhans islets in patients with type 2 diabetes. Theseesults indicate that A formation and tau phosphorylation
re also features of type 2 diabetes.
In the adult brain, alternative splicing of tau mRNA leads
o six tau isoforms which contain either three (3R) or four
d
p
tngerhans islet to Ubiquitin (D), apo-E (E), Apo(a) (F), IB1/JIP-1 (G) and
serum. Bars: (A and C) 250m, (B) 70m, (D) 200m, (E–I) 100m.
4R) microtubule-binding repeat domains (Goedert et al.,
989). The brain of healthy individuals contains similar
evels of 3R and 4R tau. 4R tau binds and stabilizes micro-
ubule more efficiently (Panda et al., 2003). Changes in the
R/4R ratio and hyperphosphorylation diminish the ability
f tau to bind microtubules. Unbounded hyperphosphory-
ated tau aggregates and forms fibrillary aggregates or tangles
n neurons, astrocytes and/or oligodendroglial cells. The tau
nclusions of these various neurodegenerative disorders or
auopathies, which include AD, differ by their proportion
f 3R/4R tau isoforms, their phosphorylation sites and ultra-
tructure (paired helical, straight or random coiled filaments).
he major doublet 64/69 kDa observed in the pancreas of
ealthy and diabetic patients may be, indicative of 4R tauopa-
hy which is characteristic of progressive supranuclear palsy
PSP) and cortico-basal degeneration (CBD) where glial tau
nclusions predominate. It is distinct from the major tau triplet
t 60, 64 and 69 kDa of AD. Further studies will be necessary
o define the exact combination of tau isoforms, the specific
hosphorylation pattern and the types of pathological fila-
ents of tau aggregates accumulating in islet cells in type 2iabetes.
Tau protein mRNA was found in equal amount in the
ancreas of patients with type 2 diabetes compared to con-
rols, whereas tau protein levels were different, which may
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Fig. 6. Synchrotron infrared microspectroscopy (SIRMS) analysis of islet amyloid deposits. (A) Epifluorescence image showing Thioflavin S positive amyloid
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deposits (arrow). (B and C) Infrared absorption image of protein structure (
f -sheet protein structure. In areas of the pancreas without Thioflavin S
-helical protein structure. Scale bar: 10m.
uggest abnormalities downstream to DNA transcription.
urther studies of representative number of cases will be
ecessary to address this question.
The in situ secondary structure of islet amyloid deposit
as not analyzed before. Using SIRMS the protein sec-
ndary structure of islet amyloid deposits was determined
n situ in the areas of Thioflavin S positive islet deposits, by
mide I infrared absorption band (1600–1700 cm−1) analysis.
he frequency of Amide I band is sensitive to protein sec-
ndary structure, where -sheet conformation absorbs near
630 cm−1. The in situ infrared absorption microspectrum
n the pancreas of patients with type 2 diabetes showed a
630 cm−1 peak corresponding to-sheet protein structure. It
as identical to the in situ infrared microspectra of beta amy-
oid deposits in senile plaques (Choo et al., 1996; Miklossy et
l., 2006b). SIMRS cannot distinguish between the beta sheet
tructure of amylin and A. However, it clearly shows that
n the affected areas of the Langerhans islet, where amylin
nd A were immune co-localized, the homogenous protein
eposits indeed correspond to amyloid substance with the
ypical beta sheet structure.
It is well established that Apo-E plays an important role in
he pathogenesis of late onset AD, with the E4 allele being a
ignificant risk factor. There have been reports of Apo-E asso-
I
c
r
l55 cm ) showed an absorbance maximum near 1630 cm representative
amyloid, the absorbance maximum was near 1655 cm−1 corresponding to
iation with amyloid deposits independently of the primary
myloid protein (Wisniewski and Frangione, 1992; Charge et
l., 1996). Apo(a), which shares a series of common features
ith Apo-E, is also implicated in the development of late
nset AD (Mooser et al., 2000). Our results showing a pos-
tive immunoreaction in association with pancreatic lesions
ot only to ubiquitin, but to Apo-E and Apo(a) as well, further
oint to the existence of common features in the pathogenesis
f AD and type 2 diabetes.
Mitogen-activated protein kinases (MAPKs) are key
nzymes involved in diverse cellular processes in response to
xtracellular stimuli. They regulate cell survival, cell death,
roliferation and/or differentiation. Activation of the ERK
orms of MAPK causes survival responses, whereas acti-
ation of the p38 and c-Jun NH2-terminal kinase (JNK)
romotes cell death. JNK, for its action, requires the pres-
nce of a scaffold protein islet-brain-1 (IB1) or C-Jun
-terminal kinase interacting protein-1 (IB1/JIP-1). The gene
APK8IP1, encoding IB1/JIP1 is a candidate for type 2
iabetes (Waeber et al., 2000) and a promoter variant of
B1/JIP1 is associated with AD (Helbecque et al., 2003). The
ytoplasmic tail of APP interacts with IB1/JIP1 and JNK is
equired for APP phosphorylation. IB-1 and JNK-1 are co-
ocalized with phosphorylated tau in neurofibrillary tangles
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Fig. 7. LPS increases APP levels in PC12 and TE671 cells. Western blot
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analysis of PC12 and TE671 cells using anti-APP 22C11 antibody detected
ncreased APP levels following 6 and 24 and 48 h of LPS exposure. The
ncreased APP levels were comparable in PC12 and TE671 cells.
n AD (Helbecque et al., 2003). The present results show that
n the pancreas of patients with type 2 diabetes, degenerating
ells of the Langerhans islets are strongly immunoreactive to
B1/JIP1 and JNK-1 as well.
Inflammatory processes play an important role in AD and
xperimentally increased APP levels and consequent A 1-
2 accumulation were observed in neurons and in the CNS in
xperimental animals following exposure to LPS. As APP is
phylogenetically stable protein we expected that LPS may
nfluence APP levels in non-neuronal cells as well. Indeed the
resent findings show that LPS induces increased APP levels
ot only in PC12 cells but in non-neuronal cells as well. The
rotective effect of insulin on neurons is well known. Here
e show that insulin decreases APP not only in PC12 cells
ut also in cells without neuronal properties. These results
urther suggest that a host reaction with elevated APP may
ccur (e.g. induced by inflammatory stimuli) in various other
rgans than the brain. They also suggest that the decreased
rotective effect of insulin in type 2 diabetes may also lead
o APP dysregulation and may be one of the mechanisms
nvolved in amyloid formation in the CNS and in various
ther organs.
Despite the fact that convincing clinical, epidemiologi-
al (reviewed by Grossman, 2003; Arvanitakis et al., 2006;
ig. 8. Western blot analysis of APP levels in PC12 and TE671 cells fol-
owing exposure to insulin. Decreased APP levels were detected following
–48 h of exposures to human recombinant insulin 100 ng/ml exposures in
C12 and in non-neuronal TE671 cells.
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lafuzoff et al., 2008) and genetic studies (Bertram et al.,
000; Duggirala et al., 2001; Myers and Goata, 2001; Tanzi
nd Bertram, 2001; Qui and Folstein, 2006) have provided
ubstantial evidence in favor of a link between AD and type 2
iabetes, studies analyzing AD-related pathology in diabetic
ases compared with non-diabetic patients failed to show
uch association (Arvanitakis et al., 2006; Alafuzoff et al.,
008). Recently, evidence for the pathological interaction
etween diabetes and presymptomatic Alzheimer’s disease
as reported (Burdo et al., 2008).
Both, AD and type 2 diabetes are slowly progressive disor-
ers with a high prevalence in the elderly population over 65
ears. In both, clinically silent amyloid deposits and patho-
ogical tau aggregates may precede by years or even decades
he clinical manifestation of dementia and type 2 diabetes.
hese clinically silent mild and moderate amyloid deposits
nd tau pathology may correspond to early, preclinical stages
f these diseases. Further prospective studies are necessary
o analyze a putative association between amyloid and tau
eposits in pancreatic islets and cortical AD pathology. The
omparison of the frequency of diabetic cases in definite AD
nd age-matched controls without AD-type cortical pathol-
gy may give further information. The analysis of the number
f diabetic patients in preclinical stages of AD (Braak stages
–IV) compared to controls without AD pathology may also
e useful.
Future prospective studies using quantitative analysis of
tandard pancreas samples taken from the head, body and tail
f the pancreas should be done. It may enable comparison of
he severity of islet A and tau pathology between diabetic
ases, between diabetic and control cases. Comparison of the
esults with cortical A and tau pathology in brains of the
ame patients and correlating them with the clinical severity
f type 2 diabetes and cognitive decline may give impor-
ant information. Further immunohistochemical analyses by
ouble labeling pancreas sections using combination of anti-
odies to various pathological proteins with amylin and with
ntibodies detecting different islet cell types (, , , , PP
ells) would give further information on the exact cellular
ocation and co-localization of pathological proteins and on
he types of islet cells involved.
In conclusion, A deposits and/or hyperphosphorylation
f tau are the most important biological markers of AD and
arious other neurodegenerative disorders. APP is a phyloge-
etically highly conserved protein which is also synthesized
y various cells outside the CNS. The present results showed
hat A deposition, hyperphosphorylation of tau, as well as
biquitin and Apo-E immunoreactivities are characteristic
eatures of type 2 diabetes. Apo(a), IB1/JIP-1 and JNK-1
re also associated with both AD and type 2 diabetes. They
ndicate that some common features are implicated in the
athogenesis of AD and type 2 diabetes and that A depo-
ition and hyperphosphorylation of tau may be part of a
idespread systemic host reaction. The inflammatory stimu-
ator and amyloidogenic LPS increases APP levels not only in
euronal but in non-neuronal cells as well. Decreased insulin
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n type 2 diabetes may also participate in APP dysregulation
nd A accumulation.
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